The synthesis and SAR of a series of indazole TRPV1 antagonists leading to the discovery of 21 (ABT-116) is described. Biological studies demonstrated potent in vitro and in vivo activity for 21, as well as suitable physicochemical and pharmacokinetic properties for advancement to clinical development for pain management. (C) 2010 Elsevier Ltd. All rights reserved.
Compounds of formula (I)
wherein R
3
, R
7
, R
9
and L are defined in the description are TRPV1 antagonists that exhibit low inhibitory activity against CYP3A4. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS
申请人:Lukin Kirill A.
公开号:US20100016611A1
公开(公告)日:2010-01-21
The invention discloses compounds of formula II:
and methods of making the compounds, which are VR
1
antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
[EN] METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS<br/>[FR] PROCÉDÉS DE PRÉPARATION D'AGENTS DESTINÉS AU SYSTÈME NERVEUX CENTRAL QUI SONT DES ANTAGONISTES DES TRPV1